GET DAILY SIGNALSPluri Inc. (PLUR) +18% Move: Partnership and Insider Support in Focus
Key Takeaways
- PLUR shares rose about 18% over the trailing 30 days, climbing from roughly $1.00 to $1.18 as of the most recent close.
- The rally was driven primarily by Pluri's late-October strategic partnership with ZEO ScientifiX to build a U.S. regenerative medicine commercialization platform.
- Chairman Alejandro Weinstein reinforced confidence through a $1.25 million securities purchase and an agreement to acquire the company's European Investment Bank loan.
- Trading volume surged around the announcement, with daily turnover peaking near 283,000 shares versus a typical range of a few thousand to roughly 20,000.
- The rebound follows a prolonged multi-month decline; shares remain well below their early-August levels above $1.80.
- Pluri remains pre-commercial and loss-making, reporting a fiscal 2026 net loss of $23.82 million.
- For additional data, review Pluri's Price Targets, Earnings, and Forecast pages.
Pluri Inc. (PLUR) Background and Market Position
Pluri Inc., formerly Pluristem Therapeutics, is an Israel-headquartered biotechnology company that develops cell-based products using a proprietary three-dimensional (3D) cell-expansion technology. The platform enables scalable, reproducible production of cells for multiple commercial verticals, including regenerative medicine, regenerative aesthetics, exosomes, and cultivated food through its Ever After Foods business.
The company's clinical pipeline includes multinational Phase III programs in muscle recovery following hip-fracture surgery and in critical limb ischemia. Its wholly owned Cellav subsidiary focuses on cell-derived ingredients and aesthetic products. Pluri holds a global patent portfolio reported at more than 140 granted patents across dozens of countries and is dual-listed on the Nasdaq and the Tel Aviv Stock Exchange. Investors follow the stock for its transition from platform development toward commercial execution, particularly in the U.S. regenerative medicine, aesthetics, and longevity markets. From what I see, this shift remains central to any longer-term outlook.
PLUR Stock Performance: Last 30 Days Versus the Quarter
Over the trailing 30 days, PLUR advanced approximately 18%, moving from a closing price of about $1.00 to $1.18 as of the most recent close. The path was not linear: shares briefly declined to an intraday low near $0.85 in mid-October before a sharp late-month rally, fueled by a surge in trading volume following the ZEO ScientifiX partnership announcement.
The 30-day gain stands in contrast to the stock's longer-term trend. Over the last quarter, PLUR fell from roughly $1.80 in early August to about $1.18, a decline of approximately 34%. In other words, the recent rebound represents a partial recovery within a broader downtrend rather than a sustained reversal, and the stock remains well below its levels from the start of the period. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Drove the Recent +18% Advance
The primary catalyst was the October 26 announcement of a definitive strategic agreement with ZEOX to expand a combined U.S. manufacturing and commercialization platform serving regenerative medicine, aesthetics, wellness, and longevity markets. Under the agreement, Pluri will grant ZEO rights to certain manufacturing technology while retaining ownership of its intellectual property and, in return, will receive shares representing 50% of ZEO's common stock at closing. The deal also gives ZEO exclusive U.S. rights to Pluri's Cellav aesthetic product line. Daily volume spiked to roughly 283,000 shares on the announcement, versus typical turnover in the low thousands, reflecting the market's focus on the partnership's commercial potential.
Supportive insider activity added to sentiment. On October 19, Pluri entered into a securities purchase agreement with Chutzpah Holdings LP, a vehicle beneficially owned by Chairman Alejandro Weinstein, to sell 833,334 shares at $1.50 per share plus warrants at a $1.65 exercise price, applying a prior $1.25 million advance. Days later, the company announced that Weinstein agreed to acquire its European Investment Bank loan, described as a vote of confidence in the business. Earlier in the month, Pluri's Ever After Foods subsidiary and Roslin Technologies reported a productivity milestone in cultivated meat, providing additional context around the company's food-technology vertical.
Quarterly Pressures and the Broader Context
The quarter's decline reflected a challenging backdrop for a pre-revenue, small-cap biotech. Pluri reported full-year fiscal 2026 results showing revenue of $1.02 million, down from $1.34 million a year earlier, and a net loss of $23.82 million, underscoring continued cash consumption. A series of SEC registration filings, including S-1, S-3, and prospectus supplements, signaled an ongoing financing and potential dilution overhang that weighed on shares through August and September.
The stock also contended with Nasdaq listing-compliance matters disclosed in SEC filings during the year, adding to investor caution. The late-October partnership and insider-led capital support then shifted sentiment, triggering the sharp recovery that defines the trailing 30 days even as the longer-term trend remained negative.
PLUR Stock Forecast Drivers: What to Watch Next
Several factors are likely to shape PLUR's trajectory going forward. The completion of the ZEO ScientifiX transaction, targeted for the fourth quarter of 2026, remains subject to ancillary agreements, approvals, and valuation deliveries, and its closing will be a key event to monitor. Investors should also watch Pluri's cash position and any additional financing activity, given the company's recurring losses and history of registration filings. Progress on Cellav's U.S. commercialization and any new revenue from the aesthetics and regenerative medicine verticals will be important indicators of execution. Finally, broader sentiment toward small-cap and pre-revenue biotech names, along with Nasdaq listing-compliance status, may continue to influence trading. As with any speculative equity, these developments carry meaningful risk and uncertainty.
Exploring Tickeron AI Trading Bots
In my own research, I often review Tickeron’s Trending AI Robots to see how different automated strategies have performed on names like PLUR. The page highlights a curated selection of the platform’s AI-driven trading bots that cover thousands of tickers, with only top-performing and most relevant ones featured. These bots span various strategies and timeframes, offering a data-driven way to evaluate signals across changing market conditions and align them with individual risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PLUR's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for PLUR moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 25 of the 29 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 62 cases where PLUR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on PLUR as a result. In 87 of 108 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
PLUR moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PLUR crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +9.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where PLUR advanced for three days, in 166 of 219 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLUR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PLUR broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PLUR entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.632) is normal, around the industry mean (3.498). P/E Ratio (-0.484) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (10.650) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. PLUR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PLUR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of stem cell production technology
Industry Biotechnology
Advertisement